Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced a board meeting scheduled for March 24, 2025, to approve and release the company’s annual results for the year ending December 31, 2024. Following the announcement, a conference call with management will be held to discuss the results, indicating the company’s commitment to transparency and stakeholder engagement.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on developing and manufacturing biopharmaceutical products, with a market presence in Hong Kong.
YTD Price Performance: 49.91%
Average Trading Volume: 339,400
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$54.55B
Find detailed analytics on 6990 stock on TipRanks’ Stock Analysis page.